Drugs

Article	Citations
Prevention and Treatment of Monkeypox	313
BNT162b2 mRNA COVID-19 Vaccine: First Approval	224
Pharmaco-Immunomodulatory Therapy in COVID-19	191
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	174
Inclisiran: First Approval	170
Lumasiran: First Approval	167
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	167
Remdesivir: First Approval	166
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	164
Nirmatrelvir Plus Ritonavir: First Approval	156
Casimersen: First Approval	135
Sacituzumab Govitecan: First Approval	134
Pemigatinib: First Approval	127
Viltolarsen: First Approval	114
Aducanumab: First Approval	114
Sotorasib: First Approval	112
Risdiplam: First Approval	99
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma	92
Acute Pancreatitis: Diagnosis and Treatment	92
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	92
TRPV1-Targeted Drugs in Development for Human Pain Conditions	91
Setmelanotide: First Approval	91
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	90
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	88
Selpercatinib: First Approval	86

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	85
Bulevirtide: First Approval	84
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?	83
Belantamab Mafodotin: First Approval	83
Remimazolam: First Approval	83
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	80
Pharmacokinetics and Pharmacodynamics of Posaconazole	79
Orelabrutinib: First Approval	79
Inhaled Liposomal Antimicrobial Delivery in Lung Infections	73
Nivolumab Plus Relatlimab: First Approval	72
New and Emerging Systemic Treatments for Atopic Dermatitis	72
Ozanimod: First Approval	72
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	71
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	69
REGN-EB3: First Approval	68
Selumetinib: First Approval	67
Tirabrutinib: First Approval	67
Lonafarnib: First Approval	66
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials	66
Fabry Disease: The Current Treatment Landscape	66
Amivantamab: First Approval	65
Pralsetinib: First Approval	63
Capmatinib: First Approval	62
Decitabine/Cedazuridine: First Approval	62
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety	61
Inebilizumab: First Approval	60
Savolitinib: First Approval	60
Belzutifan: First Approval	60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	58
Bempedoic Acid: First Approval	57
Remimazolam: A Review in Procedural Sedation	56
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	56
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	56
Deucravacitinib: First Approval	55
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review	54
Faricimab: First Approval	54
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma	53
Molnupiravir: First Approval	52
Tepotinib: First Approval	51
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	51
Casirivimab/Imdevimab: First Approval	51
Tisotumab Vedotin: First Approval	50
Targeting AMPK by Statins: A Potential Therapeutic Approach	50
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	49
Tucatinib: First Approval	49
Dostarlimab: First Approval	48
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma	48
Disitamab Vedotin: First Approval	48
Abrocitinib: First Approval	47
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation	47

Loncastuximab Tesirine: First Approval	46
Current Status of Clinical Trials on Tau Immunotherapies	46
Efgartigimod: First Approval	46
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	46
Lurbinectedin: First Approval	45
Management of Thrombotic Complications in COVID-19: An Update	45
Contezolid: First Approval	45
Filgotinib: First Approval	45
Telitacicept: First Approval	44
The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19	44
Trilaciclib: First Approval	44
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	44
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer	44
Vutrisiran: First Approval	44
Ripretinib: First Approval	44
Umbralisib: First Approval	43
Odevixibat: First Approval	43
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	43
Daprodustat: First Approval	42
Pegcetacoplan: First Approval	42
Cabotegravir Plus Rilpivirine: First Approval	42
Infigratinib: First Approval	42
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	42
Tirzepatide: First Approval	41
Naxitamab: First Approval	41
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	41
Isatuximab: First Approval	40
Envafolimab: First Approval	40
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	40
Therapeutic Options in Hereditary Optic Neuropathies	40
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma	39
Lecanemab: First Approval	39
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder	39
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs	39
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon	38
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics	38
Rimegepant: First Approval	38
Anifrolumab: First Approval	38
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	37
Satralizumab: First Approval	37
Cadonilimab: First Approval	37
Regdanvimab: First Approval	37
Givosiran: A Review in Acute Hepatic Porphyria	37
Voclosporin: First Approval	36
Tebentafusp: First Approval	36
Lazertinib: First Approval	36
Tezepelumab: First Approval	36
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	36
Ocrelizumab: A Review in Multiple Sclerosis	36
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	35
Functional Dyspepsia: Diagnostic and Therapeutic Approaches	35
Eptinezumab: First Approval	35
Evinacumab: First Approval	35
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	35
Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates	35
Melphalan Flufenamide (Melflufen): First Approval	34
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?	34
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	34
Mavacamten: First Approval	33
Tremelimumab: First Approval	33
Vadadustat: First Approval	33
Sotrovimab: First Approval	33
Fuzuloparib: First Approval	33
Daridorexant: First Approval	33
Spesolimab: First Approval	32
Mosunetuzumab: First Approval	32
Asciminib: First Approval	32
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	32
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps	31
Finerenone: First Approval	31
Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza	31
Teclistamab: First Approval	31
Avacopan: First Approval	31
Pamiparib: First Approval	31
Tixagevimab + Cilgavimab: First Approval	30
Nirsevimab: First Approval	30
Oliceridine: First Approval	30
Mobocertinib: First Approval	30
Vericiguat: First Approval	30
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	29

Olverembatinib: First Approval	29
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	29
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	29
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	29
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	29
Mirvetuximab Soravtansine: First Approval	29
Belumosudil: First Approval	28
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	28
Ansuvimab: First Approval	28
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	28
Difelikefalin: First Approval	28
Maralixibat: First Approval	28
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections	28
Novel Approaches Towards a Functional Cure of HIV/AIDS	27
Tapinarof Cream 1%: First Approval	27
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)	27
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	27
Atogepant: First Approval	27
Uveitis Therapy: The Corticosteroid Options	27
Ozoralizumab: First Approval	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	26
Donafenib: First Approval	26